You are here » Home » Companies » Company Overview » Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd.

BSE: 500660 Sector: Health care
NSE: GLAXO ISIN Code: INE159A01016
BSE 00:00 | 24 Nov 1524.95 -1.45
(-0.09%)
OPEN

1528.00

HIGH

1536.00

LOW

1523.00

NSE 00:00 | 24 Nov 1525.45 -0.25
(-0.02%)
OPEN

1529.80

HIGH

1537.90

LOW

1520.10

OPEN 1528.00
PREVIOUS CLOSE 1526.40
VOLUME 3869
52-Week high 1805.00
52-Week low 1046.40
P/E 70.08
Mkt Cap.(Rs cr) 25,834
Buy Price 1524.95
Buy Qty 8.00
Sell Price 1526.65
Sell Qty 2.00
OPEN 1528.00
CLOSE 1526.40
VOLUME 3869
52-Week high 1805.00
52-Week low 1046.40
P/E 70.08
Mkt Cap.(Rs cr) 25,834
Buy Price 1524.95
Buy Qty 8.00
Sell Price 1526.65
Sell Qty 2.00

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) - Chairman Speech

Company chairman speech

Dear Shareholders

As I complete my first year at GSK I can earnestly say that each day has been anincredibly enriching and inspiring experience. I wish to thank Annaswamy Vaidheesh for hisleadership during the last five years as a Managing Director. Vaidheesh has representedthe company with great skill and has helped it to become a positive force for change onmany important matters. I warmly welcome Sridhar Venkatesh to lead the company in our nextphase of growth to serve the patients of India. It's both humbling and exciting to be apart of GSK's rich legacy and contribute to its future. While we had an amazing year itwas the last few days of the Financial Year 2019-20 where our purpose-driven culture wastruly tested. I am pleased to inform you that amidst the global pandemic situation wecontinued to remain patient-centric and be guided by our core principles of employeesafety and wellbeing business continuity and social responsibility.

This resulted in an unstinted supply of medicines to patients in need while keepingour employees safe and healthy.

Recent events have highlighted the importance of building national and organisationalcapabilities resilience and adaptability. The government has been quick to respond to thecrisis and has recognised the need to recalibrate healthcare sector priorities to includebuilding local capabilities in manufacturing testing and diagnosis workforce skillinghospital infrastructure etc. People remain at the heart of organisation's resilience andagility. Your company continues to prioritise and invest in nurturing talent anddevelopment while also focusing on its diversity and inclusion agenda.

In the year gone by your company leveraged its digital capabilities and gained fromits skill-enhanced sales force to increase its share of voice for focus brands andsubstantially grow the number of customers' touchpoints and engagements. It makes me proudto see the focus and priority that your company demonstrated in execution of our productlaunches. The successes of Nucala and Menveo shall pave the way for introduction of strongpatient-focused products from our global pipeline in the coming years.

As a socially responsible corporate GSK Plc is collaborating with companies andresearch groups across the world working on promising COVID-19 vaccine candidates throughuse of our innovative vaccine adjuvant technology. Particularly significant is ourpartnership with Sanofi to develop an adjuvanted COVID-19 vaccine which is expected toenter clinical trials in the second half of 2020 and if successful and subject toregulatory considerations aim to complete the development required for availability bythe second half of 2021. This would be a significantly faster timeline than normal forvaccine development and teams from both companies are working on this urgently.

As we march into a post-pandemic world the next few months will be challenging butyour company's robust business model strong financials and deep relationships withcustomers will play a critical role in keeping us ahead of the curve. The future of yourcompany could not be in better hands than under the dynamic leadership of SridharVenkatesh an industry stalwart and a GSK veteran who joined us as Managing Director from1 April 2020. I believe your company is poised to embrace the change and take the businessto new heights.

As always my sincere gratitude to all stakeholders for your continued trustconfidence and support.

R.S. Karnad

Chairperson

 

.